ArticleBioscience reports2026
α-Linolenic acid-driven nano-liposomes from purslane seed oil modulate p-JAK2/p-STAT3 to combat acute liver failure.
Article in Bioscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acute liver failure (ALF) is a serious illness characterized by extensive liver cell damage and inflammation. The present study highlights the potential of purslane seed oil extract-Pluronic-modulated liposomes (PSE-PMLs) to protect against thioacetamide (TAA)-induced ALF in rats. Four groups of rats were used in the present study: normal control (NC), TAA-induced ALF, silymarin (SIL), and PSE-PML groups. SIL- and PSE-PML-pretreated groups were orally pre-administered SIL (200 mg/kg) and PSE-PMLs (500 mg/kg), respectively, for 7 days. After these pretreatments, all groups except the NC group were injected intraperitoneally with TAA (350 mg/kg) to induce ALF. Serum levels of liver biochemical markers and inflammatory cytokines, interleukin-4, and interferon-gamma were estimated. Additionally, the hepatic malondialdehyde, superoxide dismutase activity, peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, phosphorylated Janus kinase 2, phosphorylated signal transducer and activator of transcription 3, peroxisome proliferator-activated receptor-gamma, tumor protein p53, active cysteine-aspartic acid protease 3, and B-cell lymphoma 2 were assessed. A histopathological examination of the liver was also performed. The study found that pretreatment with PSE-PMLs mitigated TAA-induced biochemical and histopathological alterations, alleviating oxidative stress, dampening the overproduction of pro-inflammatory cytokines, and amending liver cell apoptosis. These pioneering findings suggest that PSE-PMLs are a promising prophylactic agent against ALF, warranting further studies in the post-injury models. The phytochemical profiling, gas chromatography-mass spectrometry, of purslane seed oil revealed α-linolenic acid (∼98%) as the predominant component, with additional sterols, tocopherols, and phenolic acids that may underlie its strong antioxidant and hepatoprotective effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.